EverSource Wealth Advisors LLC Acquires 281 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

EverSource Wealth Advisors LLC grew its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 32.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,157 shares of the medical equipment provider’s stock after acquiring an additional 281 shares during the quarter. EverSource Wealth Advisors LLC’s holdings in Intuitive Surgical were worth $514,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in the company. Gilbert & Cook Inc. boosted its position in shares of Intuitive Surgical by 6.5% in the fourth quarter. Gilbert & Cook Inc. now owns 3,437 shares of the medical equipment provider’s stock valued at $1,160,000 after acquiring an additional 211 shares during the period. TrinityPoint Wealth LLC raised its position in Intuitive Surgical by 21.5% during the 4th quarter. TrinityPoint Wealth LLC now owns 1,081 shares of the medical equipment provider’s stock valued at $365,000 after purchasing an additional 191 shares during the last quarter. Hilltop Holdings Inc. lifted its position in shares of Intuitive Surgical by 36.2% in the 4th quarter. Hilltop Holdings Inc. now owns 5,387 shares of the medical equipment provider’s stock worth $1,817,000 after purchasing an additional 1,432 shares during the period. Artisan Partners Limited Partnership lifted its holdings in Intuitive Surgical by 53.5% in the fourth quarter. Artisan Partners Limited Partnership now owns 63,851 shares of the medical equipment provider’s stock worth $21,541,000 after buying an additional 22,264 shares during the period. Finally, Mitchell Sinkler & Starr PA boosted its position in shares of Intuitive Surgical by 13.7% during the fourth quarter. Mitchell Sinkler & Starr PA now owns 1,622 shares of the medical equipment provider’s stock valued at $547,000 after purchasing an additional 195 shares in the last quarter. 83.64% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. JPMorgan Chase & Co. raised their price objective on Intuitive Surgical from $475.00 to $495.00 and gave the company an “overweight” rating in a research report on Friday, July 19th. Piper Sandler boosted their price objective on shares of Intuitive Surgical from $490.00 to $495.00 and gave the stock an “overweight” rating in a research note on Friday, July 19th. Truist Financial upped their price objective on shares of Intuitive Surgical from $450.00 to $515.00 and gave the stock a “buy” rating in a report on Tuesday, July 16th. Citigroup lifted their target price on shares of Intuitive Surgical from $512.00 to $560.00 and gave the company a “buy” rating in a report on Thursday, August 22nd. Finally, The Goldman Sachs Group began coverage on Intuitive Surgical in a research note on Thursday, May 30th. They issued a “buy” rating and a $500.00 price target on the stock. Six analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $446.45.

Intuitive Surgical Stock Performance

ISRG stock opened at $489.07 on Tuesday. The company has a market cap of $173.47 billion, a price-to-earnings ratio of 88.28, a P/E/G ratio of 5.41 and a beta of 1.39. The business’s 50-day moving average is $469.05 and its two-hundred day moving average is $426.06. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $496.18.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The company had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. During the same period in the previous year, the business posted $1.18 earnings per share. The firm’s quarterly revenue was up 14.5% compared to the same quarter last year. Equities analysts predict that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current year.

Insider Transactions at Intuitive Surgical

In other Intuitive Surgical news, SVP Henry L. Charlton sold 40,243 shares of the business’s stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the completion of the sale, the senior vice president now owns 3,001 shares of the company’s stock, valued at $1,461,006.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Intuitive Surgical news, Director Craig H. Barratt sold 1,400 shares of the company’s stock in a transaction that occurred on Tuesday, July 23rd. The shares were sold at an average price of $458.13, for a total value of $641,382.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Henry L. Charlton sold 40,243 shares of the stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the completion of the sale, the senior vice president now directly owns 3,001 shares of the company’s stock, valued at $1,461,006.84. The disclosure for this sale can be found here. Insiders sold 53,120 shares of company stock worth $25,528,753 in the last three months. Corporate insiders own 0.90% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.